Company Profile

RainDance Technologies Inc
Profile last edited on: 4/12/19      CAGE: 47N27      UEI:

Business Identifier: Genomic tools for non-invasive liquid biopsy applications for early detection and treatment of cancer, inherited, and infectious diseases.
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

749 Middlesex Turnpike
Billerica, MA 01821
   (978) 495-3300
Location: Multiple
Congr. District: 06
County: Middlesex

Public Profile

In Jnauary 2017, it was announced that Bio-Rad Laboratories Inc. had agreed to acquire private biotech RainDance Technologies Inc. for undisclosed consideration. With ties to Harvard, the Medical research Center and ESPCI in Paris, andh aving facilities in Europe and in Asia, RainDance Technologies, Inc. (RDT) is a nanotechnology company devoted to developing, and commercializing a platform for droplet-based (digital) microfluidics that accelerate human health and disease research. This platform, the Personal Laboratory System, is an integrated fluid handling system providing precise manipulation of minute amounts of fluids for a variety of industrial and research applications that include life sciences research, cancer diagnosis and detection of residual diseases. The firms’ core product, RainStorm microfluidics technology, powers next-generation sequencing and genetic testing systems to deliver dramatically superior performance, cost, interpretability, and ease of use. RainDance systems are used routinely in major academic research institutions, clinical genetics laboratories, and hospitals around the world. Rainstorm can produce up to 10 million picoliter-volume droplets per hour. Each droplet is the functional equivalent of a test tube and can contain a single molecule, reaction, or cell; this offers the scientist solutions that minimize experimental error, provide simple, high-speed workflow, and generate accurate measurements. The firm also develops genomic tools for non-invasive liquid biopsy applications for the research, early detection, and treatment of cancer, inherited, and infectious diseases. In 2015, the firm had applied for - and withdrawn - its IP

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 2 NIH $1,085,484
Project Title: Droplet based screening of molecular libraries in a microfluidic device
2008 1 NIH $100,000
Project Title: The Crystal Optimizer: Kinetic Control of Protein Crystallization

Key People / Management

  S Roopom Banerjee -- President; Chief Executive Officer

  Robert W Cunningham -- Vice President, Business Development,

  Laura L Deming -- Senior Vice President, Product Development

  Roch Kelly -- Senior Vice President, Business Operations

  Darren R Link -- Co-Founder; Chief Technology Officer

  Alfred G Merriweather -- Chief Financial Officer

  Jonathan M Rothberg -- Founder

  Jeffrey M Whynall -- Vice President of Engineering